Search results

Background We sought to determine the immunologic abnormalities in patients following SARS-CoV-2 vaccines who experience post-acute sequelae of COVID-19 (PASC)-like symptoms > 4 weeks post vaccination. In addition, we investigated whether the potential etiology was similar to PASC. Design: We...

Here's one summary:

Perhaps economists should stick to economics (which they aren't actually very good at anyways), rather than trying to do health research. This seems pretty farfetched; these small differences in life expectancy could be explained by any number of more likely factors than the precise timing of...

Early data seems to show vaccine effectiveness against BA.4 & BA.5 is about the same as against BA.2 (about 50% against infection for people boosted more than a few months ago). There are definitely some people who are getting re-infected quite soon with the next variant, but I don't think we...

Not much to take from this one, I don't think. Small N, no controls, very low naltrexone dose, vague questionnaire.

Highlights Low dose naltrexone (LDN) is safe to use in patients with long covid (LC). In patients with LC for a median 11 months, LDN reduced symptoms at 2 months. In this cohort, LDN also improved well-being in 6 of 7 parameters at 2 months. Abstract Background Up to 37.7% of patients...

Interesting, @rvallee, I had the exact opposite experience: Lots of people criticizing this article and the ones I'm seeing through my filter are mostly people who have been fairly accurate to date. I read through it and, although I agree with the conclusions about what we should do, I found a...

Nancy Klimas is trialing Etanercept and Mifepristone in GWI, though presumably not with this special injection method.

So, naively, if they think something (antibodies or antibodies + spike) is binding to ACE-2 on endothelial cells, that seems like something you could test in vitro with acute Covid or Long Covid patient plasma.

Pretty interesting to see the significantly higher reduction in cerebral blood flow and that it wasn't correlated with VO2max (and in a relatively large cohort), but I think we need to see the CBF results replicated in a patient group that wasn't referred to a cardiology clinic, as these...

Background: Orthostatic intolerance (OI) is a core finding in individuals with myalgic encephalomyelitis /chronic fatigue syndrome (ME/CFS). Deconditioning is often proposed as an important determinant for OI. Deconditioning can be objectively classified using the predicted peak oxygen...

Introduction: In patients with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) a higher-than-normal resting heart rate has been reported in a number of studies. As heart rate is linked to stroke volume, the present study explored the relationship between the supine heart rate and...

This is pretty funny as an academic paper. They multiplied the number of estimated number of US cases of Covid by the ONS Long Covid survey estimates (with a few adjustments) and report the results. I have an alternate method: Let's just say it's probably about the same as the UK, near as we...

BA.2.75 sure is worrying (or could still turn out to be nothing), but calculating a relative growth advantage with a few dozen sequences over the last month and with who knows what ascertainment bias (almost all the sequences are from India, mostly from one state), isn't really going to tell us...

Sounds like they found elevated WASF3 protein in muscle.

I think this is a useful study as it gives us an idea of the ratio of people self-reporting Long Covid (8-17% for any symptom 12+ weeks, 1.2–4.8% for limiting day-to-day function 12+ weeks) versus the number of people with a LC diagnosis in the health records (0.4%), at least in the UK.

Has anyone confirmed the IDO2 genetic mutations in any other cohort or are they still basing this on the 20 severely ill patients alone? It's confusing to me why we've heard so much about yeast experiments and little about confirming the genetic basis for the hypothesis, which seems like it...

Even the Bateman Horne study doesn't look great. Primary outcome: Chalder Fatigue Scale. Secondary outcomes: Adverse events, SF-36, Patient Global Impression of Change Questionnaire. There is mention of "hours of upright activity, functional capacity (upright activity, steps, cognition, and...

There was a recent study using VA data that claimed something along these lines, but I don't think it's even measuring re-infections (and it's looking more at post-Covid risk of various bad outcomes than Long Covid as in the thing that is similar to ME). Doesn't tell us anything really. The ONS...

A few people in that Twitter thread talking about being misdiagnosed with ME and then later receiving a diagnosis of lupus or Sjogren's, which makes me wonder how common that may be. If you had a significant number of people who had an autoimmune disease misdiagnosed as ME, then maybe the high...